Efficacy and safety of evolocumab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia: 12-week primary results of the HUA TUO 华佗 randomized clinical trialed Item

The above graphical abstract and the Chinese and Japanese translations of the abstract represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).